AtaiBeckley Inc. (ATAI)
NASDAQ: ATAI · Real-Time Price · USD
3.890
+0.500 (14.75%)
At close: Mar 9, 2026, 4:00 PM EDT
3.849
-0.041 (-1.05%)
After-hours: Mar 9, 2026, 7:57 PM EDT
AtaiBeckley Revenue
AtaiBeckley had revenue of $1.07M in the quarter ending December 31, 2025, a decrease of -21,420.00%. This brings the company's revenue in the last twelve months to $3.02M, up 811.78% year-over-year. In the year 2024, AtaiBeckley had annual revenue of $308.00K, down -1.91%.
Revenue (ttm)
$3.02M
Revenue Growth
+811.78%
P/S Ratio
468.16
Revenue / Employee
$55,889
Employees
54
Market Cap
1.41B
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Ardelyx | 407.32M |
| Monte Rosa Therapeutics | 181.54M |
| Immatics | 56.67M |
| EyePoint | 31.37M |
| Zenas BioPharma | 15.00M |
ATAI News
- 3 days ago - AtaiBeckley Inc. (ATAI) Analyst/Investor Day Transcript - Seeking Alpha
- 3 days ago - AtaiBeckley Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business and Clinical Update - GlobeNewsWire
- 10 days ago - AtaiBeckley Inc. (ATAI) Discusses Positive Topline Results From Exploratory Phase IIa Study of EMP-01 in Social Anxiety Disorder Transcript - Seeking Alpha
- 11 days ago - AtaiBeckley Touts Social Anxiety Breakthrough With Phase 2 Trial Data - Benzinga
- 11 days ago - AtaiBeckley Announces Positive Topline Results from an Exploratory Phase 2a Trial of EMP-01 (oral R-MDMA) in Social Anxiety Disorder - GlobeNewsWire
- 17 days ago - AtaiBeckley To Host Virtual Investor Day on March 6, 2026 - GlobeNewsWire
- 7 weeks ago - AtaiBeckley Participates in the 64th Annual ACNP Meeting with Two Scientific Poster Presentations and Hot Topic Presentation - GlobeNewsWire
- 2 months ago - AtaiBeckley Provides Update and Outlook for 2026 Ahead of J.P. Morgan Healthcare Conference - GlobeNewsWire